Please assess the completion status of the following clinical trial:

Trial Title: Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Patients with HCC, NSCLC, RCC or CRC treated with an approved antiangiogenic drug (bevacizumab, sorafenib, sunitinib)\*~* Patients with at least one measurable lesion. Lesions must be measurable by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumours (RECIST)~Exclusion Criteria:~* Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.~* Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results~* Known or suspected allergy to the investigational agent or any agent given in association with this trial -_\> allergy~* MRI contraindications: implants (pacemaker)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Control group n=20
- 2 (Type: None): investigational group (cancer patients) n=40 patients treated with antiangiogenic agent

Based on this trial design, predict the completion outcome and termination type (if applicable).